DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Voxelotor can Promote Long-Term Benefits in Teens, Adults With SCD, Latest Clinical Data Show
Global Blood Therapeutics’ lead therapeutic candidate voxelotor can induce rapid, robust, and sustained improvements in the amount of hemoglobin in adolescents and adults with sickle cell disease (SCD), according to interim results from the first part of a Phase 3 trial.
The latest results of GBT’s clinical program for voxelotor were recently presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego.
Findings from the ongoing Phase 3 HOPE trial (NCT03036813) were revealed in a presentation titled “Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031) at 24-weeks, a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease.”
The two-part study is designed to evaluate the effectiveness and safety of voxelotor in sickle cell patients ages 12 to 65.


Related Content
-
education & researchTransition: Taking Charge of Your Health and Health CareTransition is the process of young peopl...
-
education & researchThe first two years of life in sickle cell anemia infants: A results of a comprehensive longitudinal studyInfancy is a critical time during which ...
-
news & eventsImara’s IMR-687 for SCD Receives FDA Rare Pediatric Disease DesignationThe U.S. Food and Drug Administration (F...
-
news & eventsReview Board Finds Global Blood’s Sickle Cell Disease Therapy Voxelotor Is SafeAn independent review board has found Gl...
-
news & eventsFDA agrees accelerated approval pathway for GBT’s voxelotorGlobal Blood Therapeutics, Inc. ...
-
news & eventsNew Research Suggests SANGUINATE™ Reduces the Number of Sickled Red Blood Cells in Patients with Vaso-Occlusive Cr...SANGUINATE™, the only investigational ...
-
videos & visualsSickle Cell Disease Can’t Stop Alliyahhttps://www.youtube.com/watch?v=pcFdP9cq...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.